Drug-maker in $1.6bn deal

THE generic drug-maker Mallinckrodt has reached a tentative $1.6bn (£1.2bn) deal to settle lawsuits over its role in the US opioids crisis.

The deal is intended to end hundreds of lawsuits faced by the UK-based company over opioids.

The company said that it had an agreement with a key committee of lawyers representing thousands of US local governments suing various drug industry players over opioids.